Literature DB >> 17346747

The natural history of relapses in multiple sclerosis.

Timothy Vollmer1.   

Abstract

Relapses are a defining feature of multiple sclerosis (MS), serving as the basis for categorizing the different phases of the disease, and providing a means of measuring treatment success, following disease activity, and defining prognostic features. While the dissociation between relapses and disease progression indicates the boundaries of relapse history in determining disease course over time, it also highlights the importance of relapses to overall disease evolution. A broad understanding of relapse definition and dynamics is important to promote accurate diagnosis, patient management, and treatment decisions. In an attempt to describe the underlying etiology and clinical impact of relapses in MS, this review will examine relapse findings from natural history studies, the utility of relapse as a predictor of disease course, the factors that may contribute to relapse, and data on relapse resolution. The relationship of clinical relapses to MRI disease activity and to the onset of progressive disease will also be addressed.

Entities:  

Mesh:

Year:  2007        PMID: 17346747     DOI: 10.1016/j.jns.2007.01.065

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  27 in total

1.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

2.  Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects.

Authors:  Matthew E Sweeney; Joyce G Slusser; Sharon G Lynch; Stephen H Benedict; Sharon L Garcia; Laura Rues; Steven M LeVine
Journal:  Int Immunopharmacol       Date:  2011-07-30       Impact factor: 4.932

Review 3.  Clinical Course of Multiple Sclerosis.

Authors:  Sylvia Klineova; Fred D Lublin
Journal:  Cold Spring Harb Perspect Med       Date:  2018-09-04       Impact factor: 6.915

Review 4.  Economic burden of multiple sclerosis: a systematic review of the literature.

Authors:  Huseyin Naci; Rachael Fleurence; Julie Birt; Amy Duhig
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.

Authors:  Martina Novotna; M Mateo Paz Soldán; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; John H Noseworthy; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2015-07-24       Impact factor: 9.910

6.  Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis.

Authors:  Nikos Gorgoraptis; Claudia A M Wheeler-Kingshott; Thomas M Jenkins; Daniel R Altmann; David H Miller; Alan J Thompson; Olga Ciccarelli
Journal:  Mult Scler       Date:  2010-03-09       Impact factor: 6.312

Review 7.  Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes.

Authors:  Florian Deisenhammer
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  Elevated ATG5 expression in autoimmune demyelination and multiple sclerosis.

Authors:  Mehrdad Alirezaei; Howard S Fox; Claudia T Flynn; Craig S Moore; Andrea L O Hebb; Ricardo F Frausto; Virender Bhan; William B Kiosses; J Lindsay Whitton; George S Robertson; Stephen J Crocker
Journal:  Autophagy       Date:  2009-02-05       Impact factor: 16.016

9.  Elevated concentration of C-reactive protein is associated with pregnancy-related co-morbidities but not with relapse activity in multiple sclerosis.

Authors:  Anna Jalkanen; Tommi Kauko; Janne O Koskinen; Matti E Waris; Laura Airas
Journal:  Neurol Sci       Date:  2014-10-12       Impact factor: 3.307

Review 10.  Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.

Authors:  Patricia K Coyle; Anne Gocke; Megan Vignos; Scott D Newsome
Journal:  Adv Ther       Date:  2021-06-01       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.